Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA2 | P42262 | 1/20 | 0.45 |
| ▸ | UBE2M | P61081 | 1/20 | 0.42 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.42 |
| ▸ | CCR1 | P32246 | 7/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
| ▸ | USP7 | Q93009 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25229143 | 0.91 | GRIA2 (0.45) | GRIA2UBE2MDCUN1D1CCR1ATM | |
| SCHEMBL30469087 | 0.91 | GRIA2 (0.45) | GRIA2UBE2MDCUN1D1CCR1ATM | |
| SCHEMBL25237518 | 0.85 | TGM2 (0.40) | CCR1TRPV1CNR1CNR2LMNA | |
| SCHEMBL25279946 | 0.81 | GRIA2 (0.45) | GRIA2CCR1CNR1CNR2SCN9A | |
| SCHEMBL25278823 | 0.78 | CCR1 (0.48) | CCR1TRPV1LMNAPOLBSCN9A | |
| SCHEMBL25231637 | 0.77 | SCN9A (0.50) | CCR1TRPV1SCN9ACYP2C9 | |
| SCHEMBL30469077 | 0.77 | LMNA (0.50) | GRIA2CCR1TRPV1LMNAPOLB | |
| SCHEMBL25274909 | 0.77 | LMNA (0.50) | GRIA2CCR1TRPV1LMNAPOLB | |
| SCHEMBL25236478 | 0.76 | TGM2 (0.43) | CCR1TRPV1CNR1CNR2SCN9A | |
| SCHEMBL30469078 | 0.76 | TGM2 (0.43) | CCR1TRPV1CNR1CNR2SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230202985-A1 | Indoles, Indazoles, and Related Analogs for Inhibiting YAP/TAZ-TEAD | CISTIM LEUVEN VZW (BE) | 2023-06-29 | — | — | US | disclosed |
| US-20230202985-A1 | Indoles, Indazoles, and Related Analogs for Inhibiting YAP/TAZ-TEAD | CISTIM LEUVEN VZW (BE) | 2023-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230202985-A1 | Indoles, Indazoles, and Related Analogs for Inhibiting YAP/TAZ-TEAD | YAP1, TEAD2, TEAD3 | GRIA2 3796/4885UBE2M 3081/4885DCUN1D1 3162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.